Cargando…
Protective Role for LPA(3) in Cardiac Hypertrophy Induced by Myocardial Infarction but Not by Isoproterenol
Background: We previously reported that lysophosphatidic acid (LPA) promoted cardiomyocyte hypertrophy in vitro via one of its G protein-coupled receptor subtypes, LPA(3). In this study, we examined the role of LPA(3) in cardiac hypertrophy induced by isoproterenol (ISO) and myocardial infarction. M...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5447740/ https://www.ncbi.nlm.nih.gov/pubmed/28611684 http://dx.doi.org/10.3389/fphys.2017.00356 |
_version_ | 1783239406551826432 |
---|---|
author | Cai, Lin Fan, Guangpu Wang, Fang Liu, Si Li, Tiewei Cong, Xiangfeng Chun, Jerold Chen, Xi |
author_facet | Cai, Lin Fan, Guangpu Wang, Fang Liu, Si Li, Tiewei Cong, Xiangfeng Chun, Jerold Chen, Xi |
author_sort | Cai, Lin |
collection | PubMed |
description | Background: We previously reported that lysophosphatidic acid (LPA) promoted cardiomyocyte hypertrophy in vitro via one of its G protein-coupled receptor subtypes, LPA(3). In this study, we examined the role of LPA(3) in cardiac hypertrophy induced by isoproterenol (ISO) and myocardial infarction. Methods: In vitro, neonatal rat cardiomyocytes (NRCMs) were subjected to LPA(3) knocked-down, or pretreated with a β-adrenergic receptor (β-AR) antagonist (propranolol) before LPA/ISO treatment. Cardiomyocyte size and hypertrophic gene (ANP, BNP) mRNA levels were determined. In vivo, [Formula: see text] and wild-type mice were implanted subcutaneously with an osmotic mini-pump containing ISO or vehicle for 2 weeks; echocardiography was performed to determine the heart weight/body weight ratio, cardiomyocyte cross-sectional area, and level of ANP mRNA expression. [Formula: see text] and wild-type mice were subjected to permanent coronary artery ligation or sham surgery for 4 weeks; cardiac function, including the degree of hypertrophy and infarction size, was determined. Results: In vitro, we found that knocked-down LPA(3) in NRCMs did not attenuate ISO-induced hypertrophy, and propranolol was unable to abolish LPA-induced hypertrophy. In vivo, chronic ISO infusion caused cardiac hypertrophy in wild-type mice, while hypertrophic responses to ISO infusion were not attenuated in [Formula: see text] mice. However, in a myocardial infarction (MI) model, [Formula: see text] mice exhibited reduced cardiac hypertrophy compared to wild-type mice at 4 weeks post-MI, which was associated with reduced cardiac function and increased infarct size. Conclusions: Our data show that LPA(3) appears to play a protective role in myocardial hypertrophy post-MI, but does not appear to be involved in the hypertrophy that occurs in response to β-AR stimulation in vivo and in vitro. These results implicate LPA-LPA(3) lipid signaling in cardiac hypertrophy occurring after pathological insults like MI, which presents a new variable in β-AR-independent hypertrophy. Thus, modulation of LPA(3) signaling might represent a new strategy for preventing the stressed myocardium from ischemia injury. |
format | Online Article Text |
id | pubmed-5447740 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-54477402017-06-13 Protective Role for LPA(3) in Cardiac Hypertrophy Induced by Myocardial Infarction but Not by Isoproterenol Cai, Lin Fan, Guangpu Wang, Fang Liu, Si Li, Tiewei Cong, Xiangfeng Chun, Jerold Chen, Xi Front Physiol Physiology Background: We previously reported that lysophosphatidic acid (LPA) promoted cardiomyocyte hypertrophy in vitro via one of its G protein-coupled receptor subtypes, LPA(3). In this study, we examined the role of LPA(3) in cardiac hypertrophy induced by isoproterenol (ISO) and myocardial infarction. Methods: In vitro, neonatal rat cardiomyocytes (NRCMs) were subjected to LPA(3) knocked-down, or pretreated with a β-adrenergic receptor (β-AR) antagonist (propranolol) before LPA/ISO treatment. Cardiomyocyte size and hypertrophic gene (ANP, BNP) mRNA levels were determined. In vivo, [Formula: see text] and wild-type mice were implanted subcutaneously with an osmotic mini-pump containing ISO or vehicle for 2 weeks; echocardiography was performed to determine the heart weight/body weight ratio, cardiomyocyte cross-sectional area, and level of ANP mRNA expression. [Formula: see text] and wild-type mice were subjected to permanent coronary artery ligation or sham surgery for 4 weeks; cardiac function, including the degree of hypertrophy and infarction size, was determined. Results: In vitro, we found that knocked-down LPA(3) in NRCMs did not attenuate ISO-induced hypertrophy, and propranolol was unable to abolish LPA-induced hypertrophy. In vivo, chronic ISO infusion caused cardiac hypertrophy in wild-type mice, while hypertrophic responses to ISO infusion were not attenuated in [Formula: see text] mice. However, in a myocardial infarction (MI) model, [Formula: see text] mice exhibited reduced cardiac hypertrophy compared to wild-type mice at 4 weeks post-MI, which was associated with reduced cardiac function and increased infarct size. Conclusions: Our data show that LPA(3) appears to play a protective role in myocardial hypertrophy post-MI, but does not appear to be involved in the hypertrophy that occurs in response to β-AR stimulation in vivo and in vitro. These results implicate LPA-LPA(3) lipid signaling in cardiac hypertrophy occurring after pathological insults like MI, which presents a new variable in β-AR-independent hypertrophy. Thus, modulation of LPA(3) signaling might represent a new strategy for preventing the stressed myocardium from ischemia injury. Frontiers Media S.A. 2017-05-30 /pmc/articles/PMC5447740/ /pubmed/28611684 http://dx.doi.org/10.3389/fphys.2017.00356 Text en Copyright © 2017 Cai, Fan, Wang, Liu, Li, Cong, Chun and Chen. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Physiology Cai, Lin Fan, Guangpu Wang, Fang Liu, Si Li, Tiewei Cong, Xiangfeng Chun, Jerold Chen, Xi Protective Role for LPA(3) in Cardiac Hypertrophy Induced by Myocardial Infarction but Not by Isoproterenol |
title | Protective Role for LPA(3) in Cardiac Hypertrophy Induced by Myocardial Infarction but Not by Isoproterenol |
title_full | Protective Role for LPA(3) in Cardiac Hypertrophy Induced by Myocardial Infarction but Not by Isoproterenol |
title_fullStr | Protective Role for LPA(3) in Cardiac Hypertrophy Induced by Myocardial Infarction but Not by Isoproterenol |
title_full_unstemmed | Protective Role for LPA(3) in Cardiac Hypertrophy Induced by Myocardial Infarction but Not by Isoproterenol |
title_short | Protective Role for LPA(3) in Cardiac Hypertrophy Induced by Myocardial Infarction but Not by Isoproterenol |
title_sort | protective role for lpa(3) in cardiac hypertrophy induced by myocardial infarction but not by isoproterenol |
topic | Physiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5447740/ https://www.ncbi.nlm.nih.gov/pubmed/28611684 http://dx.doi.org/10.3389/fphys.2017.00356 |
work_keys_str_mv | AT cailin protectiveroleforlpa3incardiachypertrophyinducedbymyocardialinfarctionbutnotbyisoproterenol AT fanguangpu protectiveroleforlpa3incardiachypertrophyinducedbymyocardialinfarctionbutnotbyisoproterenol AT wangfang protectiveroleforlpa3incardiachypertrophyinducedbymyocardialinfarctionbutnotbyisoproterenol AT liusi protectiveroleforlpa3incardiachypertrophyinducedbymyocardialinfarctionbutnotbyisoproterenol AT litiewei protectiveroleforlpa3incardiachypertrophyinducedbymyocardialinfarctionbutnotbyisoproterenol AT congxiangfeng protectiveroleforlpa3incardiachypertrophyinducedbymyocardialinfarctionbutnotbyisoproterenol AT chunjerold protectiveroleforlpa3incardiachypertrophyinducedbymyocardialinfarctionbutnotbyisoproterenol AT chenxi protectiveroleforlpa3incardiachypertrophyinducedbymyocardialinfarctionbutnotbyisoproterenol |